ES2634019T3 - Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido - Google Patents
Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido Download PDFInfo
- Publication number
- ES2634019T3 ES2634019T3 ES14712945.6T ES14712945T ES2634019T3 ES 2634019 T3 ES2634019 T3 ES 2634019T3 ES 14712945 T ES14712945 T ES 14712945T ES 2634019 T3 ES2634019 T3 ES 2634019T3
- Authority
- ES
- Spain
- Prior art keywords
- crystalline form
- acetic acid
- triethylamine salt
- substituted thiazolyl
- thiazolyl acetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 title abstract 5
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 title abstract 2
- -1 thiazolyl acetic acid Chemical class 0.000 title abstract 2
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
- C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Abstract
Una forma cristalina de la sal de trietilamina del ácido (2Z)-2-(2-amino-5-clorotiazol-4-il)-2-(3-N-tertbutoxicarbonilaminopropoxiimino) acético; en la que la forma cristalina se caracteriza por al menos una de las siguientes propiedades: (a) un patrón de difracción de rayos X que comprende picos de difracción a valores 2θ de 5.00±0.20, 12.92±0.20, 15.00±0.20, 16.92±0.20, 22.36±0.20, 23.36±0.20 y 24.54±0.20; (b) una temperatura de inicio de fusión de aproximadamente 139°C; o (c) parámetros cristalinos a 293 K que comprenden (i) un sistema cristalino monoclínico, (ii) un grupo espacial P21/c, y (iii) dimensiones unitarias de la celda sustancialmente igual a: a >= 8.587(4) Å, b >= 35.594(12) Å, c >= 8.308(3) Å y β >=100.63(4)°.
Description
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779091P | 2013-03-13 | 2013-03-13 | |
| US201361779091P | 2013-03-13 | ||
| PCT/US2014/021080 WO2014164187A1 (en) | 2013-03-13 | 2014-03-06 | Crystalline form of a substituted thiazolylacetic acid triethylamine salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2634019T3 true ES2634019T3 (es) | 2017-09-26 |
Family
ID=50382685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14712945.6T Active ES2634019T3 (es) | 2013-03-13 | 2014-03-06 | Forma cristalina de una sal de trietilamina del ácido tiazolilacético sustituido |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9139542B2 (es) |
| EP (1) | EP2970164B1 (es) |
| JP (2) | JP6404309B2 (es) |
| KR (1) | KR20150126368A (es) |
| CN (1) | CN105121417B (es) |
| AU (1) | AU2014249611B2 (es) |
| BR (1) | BR112015022600A2 (es) |
| CA (1) | CA2902724A1 (es) |
| EA (1) | EA027911B1 (es) |
| ES (1) | ES2634019T3 (es) |
| GE (1) | GEP201706779B (es) |
| IL (1) | IL240600A0 (es) |
| MD (1) | MD4719C1 (es) |
| MX (1) | MX351963B (es) |
| PH (1) | PH12015502067A1 (es) |
| SG (1) | SG11201507221VA (es) |
| TW (1) | TWI627165B (es) |
| UA (1) | UA115087C2 (es) |
| WO (1) | WO2014164187A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3978485B1 (en) | 2019-05-31 | 2026-02-11 | Hyundai Pharm Co., Ltd. | Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4372952A (en) | 1978-07-31 | 1983-02-08 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
| US4284631A (en) | 1978-07-31 | 1981-08-18 | Fujisawa Pharmaceutical Co., Ltd. | 7-Substituted cephem compounds and pharmaceutical antibacterial compositions containing them |
| US4341775A (en) | 1978-09-11 | 1982-07-27 | Fujisawa Pharmaceutical Co., Ltd. | Cephem compounds |
| GB2033377B (en) | 1978-09-11 | 1983-05-05 | Fujisawa Pharmaceuticalco Ltd | Cephem compounds and processes for preparation thereof |
| US4220761A (en) | 1978-09-12 | 1980-09-02 | Fujisawa Pharmaceutical Co., Ltd. | 7-[Substituted oximinoacetamido]-3-[hydroxy alkyltetrazolo]cephalosporin derivatives |
| DE2945248A1 (de) | 1978-11-13 | 1980-05-22 | Fujisawa Pharmaceutical Co | Cephem-verbindungen, verfahren zu ihrer herstellung und sie enthaltende antibakterielle pharmazeutische mittel |
| DE3177090D1 (en) * | 1980-12-31 | 1989-09-28 | Fujisawa Pharmaceutical Co | 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof |
| JP2519054B2 (ja) | 1986-06-09 | 1996-07-31 | 武田薬品工業株式会社 | 新規セフェム化合物 |
| AU1630988A (en) | 1987-05-30 | 1988-12-01 | Kyoto Pharmaceutical Industries, Ltd. | Cephalosporin compound and pharmaceutical composition thereof |
| JPH04221388A (ja) * | 1990-12-20 | 1992-08-11 | Asahi Chem Ind Co Ltd | セファロスポリン化合物およびその製造法 |
| TWI335332B (en) | 2001-10-12 | 2011-01-01 | Theravance Inc | Cross-linked vancomycin-cephalosporin antibiotics |
| ITMI20012363A1 (it) | 2001-11-09 | 2003-05-09 | Antibioticos Spa | Metodo per la sintesi di catene laterali di cefalosporine |
| ES2384707T3 (es) | 2002-05-24 | 2012-07-11 | Theravance, Inc. | Antibióticos entrecruzados de glucopéptidos y cefalosporinas |
| GB0416379D0 (en) | 2004-07-22 | 2004-08-25 | Sandoz Ag | Organic compounds |
| TW200637559A (en) | 2005-03-29 | 2006-11-01 | Shionogi & Co | 3-propenylcefem derivative |
-
2014
- 2014-03-06 TW TW103107729A patent/TWI627165B/zh not_active IP Right Cessation
- 2014-03-06 CN CN201480013807.7A patent/CN105121417B/zh active Active
- 2014-03-06 MD MDA20150099A patent/MD4719C1/ro active IP Right Grant
- 2014-03-06 BR BR112015022600A patent/BR112015022600A2/pt active Search and Examination
- 2014-03-06 MX MX2015012146A patent/MX351963B/es active IP Right Grant
- 2014-03-06 GE GEAP201413956A patent/GEP201706779B/en unknown
- 2014-03-06 SG SG11201507221VA patent/SG11201507221VA/en unknown
- 2014-03-06 JP JP2016500718A patent/JP6404309B2/ja active Active
- 2014-03-06 CA CA2902724A patent/CA2902724A1/en not_active Abandoned
- 2014-03-06 UA UAA201509929A patent/UA115087C2/uk unknown
- 2014-03-06 KR KR1020157026105A patent/KR20150126368A/ko not_active Withdrawn
- 2014-03-06 ES ES14712945.6T patent/ES2634019T3/es active Active
- 2014-03-06 EP EP14712945.6A patent/EP2970164B1/en active Active
- 2014-03-06 AU AU2014249611A patent/AU2014249611B2/en not_active Ceased
- 2014-03-06 WO PCT/US2014/021080 patent/WO2014164187A1/en not_active Ceased
- 2014-03-06 US US14/198,975 patent/US9139542B2/en active Active
- 2014-03-06 EA EA201591708A patent/EA027911B1/ru unknown
-
2015
- 2015-08-17 IL IL240600A patent/IL240600A0/en unknown
- 2015-09-11 PH PH12015502067A patent/PH12015502067A1/en unknown
-
2018
- 2018-08-15 JP JP2018152961A patent/JP2018197256A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN105121417A (zh) | 2015-12-02 |
| WO2014164187A1 (en) | 2014-10-09 |
| EA027911B1 (ru) | 2017-09-29 |
| UA115087C2 (uk) | 2017-09-11 |
| MD4719B1 (ro) | 2020-10-31 |
| BR112015022600A2 (pt) | 2017-07-18 |
| CA2902724A1 (en) | 2014-10-09 |
| CN105121417B (zh) | 2017-11-17 |
| JP2016512257A (ja) | 2016-04-25 |
| PH12015502067B1 (en) | 2016-01-25 |
| JP6404309B2 (ja) | 2018-10-10 |
| SG11201507221VA (en) | 2015-10-29 |
| EP2970164B1 (en) | 2017-05-03 |
| MX351963B (es) | 2017-11-06 |
| AU2014249611B2 (en) | 2017-12-21 |
| PH12015502067A1 (en) | 2016-01-25 |
| TWI627165B (zh) | 2018-06-21 |
| IL240600A0 (en) | 2015-09-24 |
| TW201444810A (zh) | 2014-12-01 |
| MX2015012146A (es) | 2015-11-25 |
| MD20150099A2 (ro) | 2016-02-29 |
| MD4719C1 (ro) | 2021-05-31 |
| US9139542B2 (en) | 2015-09-22 |
| HK1214596A1 (en) | 2016-07-29 |
| EA201591708A1 (ru) | 2016-01-29 |
| EP2970164A1 (en) | 2016-01-20 |
| GEP201706779B (en) | 2017-11-27 |
| KR20150126368A (ko) | 2015-11-11 |
| AU2014249611A1 (en) | 2015-09-17 |
| US20140275554A1 (en) | 2014-09-18 |
| JP2018197256A (ja) | 2018-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3351539T3 (fi) | Kiteinen monohydraattikompleksi 1-syaani-2-(4-syklopropyylibentsyyli)-4-(ß-D-glukopyranos-1-yyli)bentseenistä ja L-proliinista kidevedessä (1:1:1), menetelmät sen valmistamiseksi ja sen käyttö SGLT-estäjänä | |
| ES2656623T3 (es) | Forma cristalina l de dimaleato inhibidor de tirosina cinasa y métodos de preparación de la misma | |
| AR106141A1 (es) | Métodos e intermediarios para la preparación de derivados de ácidos biliares | |
| AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
| FR3012140B1 (fr) | Unite et procede pour la purification de methacrylate de methyle brut | |
| CR20150663A (es) | Derivados de diazacarbazol como ligandos de tau para pet | |
| FR3001970B1 (fr) | Procede de preparation d'acide 2,5-furane dicarboxylique | |
| BR112012018681A2 (pt) | uso de um sal de lítio, e, processos para purificar um ácido graxo, para preparar um ácido graxo e para estender o comprimento de um ácido graxo | |
| BR112016010862A8 (pt) | formas mórficas de ésteres de hexadeciloxipropil-fosfonato, seu método de preparo e composição compreendendo a dita forma mórfica | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| MX373700B (es) | Composicion acuosa novedosa. | |
| FR3012290B1 (fr) | Procede de preparation de sels d'acides carboxyliques herbicides | |
| BR112017010932A2 (pt) | método para recuperar cristais de ácido succínico com o uso de tensoativos durante a cristalização e cristais resultantes | |
| CL2015002065A1 (es) | Método para mejorar composiciones de sal de nitrato por medio de ácido nítrico para su uso con medio de transferencia de calor o medio de almacenamiento de calor. | |
| MX379184B (es) | Sal sodica de inhibidor de transportador de acido urico y su forma cristalina. | |
| JP2016516014A5 (es) | ||
| PE20171259A1 (es) | Compuestos | |
| ES2525528T3 (es) | Amicolamicina, método para su producción y su utilización | |
| BR112015029745A2 (pt) | método para desidratação de ácidos carboxílicos alfa-substituídos | |
| FR3008970B1 (fr) | Procede de production d'alcools par hydrogenation catalytique d'acide levulinique en une etape | |
| JP2013059750A5 (es) | ||
| UY33510A (es) | Procedimiento de obtencion de la forma cristalina a del febuxostat | |
| CU20160005A7 (es) | Nueva sal de la 3-[(3-{[4-(4-morfolinilmetil)-1 h-pirrol-2-il]metilen}-2-0xo-2,3-dihidro-1 h-indol-5-il)metil]-1,3-tiazolidina-2,4-diona, su procedimiento de preparación, y las formulaciones que la contienen | |
| WO2014167509A3 (en) | Loxoprofen polymorphs and process for preparation of the same | |
| ES2481140B1 (es) | Proceso para la preparación en forma cristalina de tibolona, (7 alfa, 17 alfa)-17-hidroxi-7-metil-19-norpregn-5(10)-en-20-in-3-ona |